Erik Teugels

2.6k total citations
72 papers, 2.0k citations indexed

About

Erik Teugels is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erik Teugels has authored 72 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 27 papers in Oncology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erik Teugels's work include Lung Cancer Treatments and Mutations (19 papers), BRCA gene mutations in cancer (17 papers) and HER2/EGFR in Cancer Research (8 papers). Erik Teugels is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), BRCA gene mutations in cancer (17 papers) and HER2/EGFR in Cancer Research (8 papers). Erik Teugels collaborates with scholars based in Belgium, United States and Slovenia. Erik Teugels's co-authors include Jacques De Grève, Ijeoma Adaku Umelo, Peter Kronenberger, Sylvia De Brakeleer, Caroline Geers, Gang Chen, Lore Decoster, Alain Ghysen, Erica Sermijn and Gang Chen and has published in prestigious journals such as Nature, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Erik Teugels

68 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Teugels Belgium	26	1.2k	693	561	560	427	72	2.0k
Karl Dykema United States	25	1.3k 1.1×	465 0.7×	478 0.9×	543 1.0×	220 0.5×	41	2.0k
Sunil Pancholi United Kingdom	20	738 0.6×	947 1.4×	714 1.3×	417 0.7×	398 0.9×	41	1.8k
Teresa Ward New Zealand	13	1.2k 1.1×	974 1.4×	258 0.5×	503 0.9×	308 0.7×	15	1.8k
Matthew V. Lorenzi United States	28	1.5k 1.3×	920 1.3×	586 1.0×	367 0.7×	169 0.4×	64	2.6k
Ciara Metcalfe United States	14	1.1k 0.9×	588 0.8×	196 0.3×	197 0.4×	306 0.7×	33	1.6k
Laufey T. Ámundadóttir United States	21	1.0k 0.9×	641 0.9×	170 0.3×	287 0.5×	385 0.9×	47	1.7k
Michael Dodge United States	12	1.8k 1.5×	648 0.9×	186 0.3×	277 0.5×	221 0.5×	16	2.2k
Joshua M. Francis United States	16	1.5k 1.3×	454 0.7×	221 0.4×	540 1.0×	269 0.6×	26	2.1k
Marion J.G. Bussemakers Netherlands	27	2.1k 1.8×	573 0.8×	1.1k 2.0×	899 1.6×	263 0.6×	40	3.2k
Vera Fantl United Kingdom	16	1.3k 1.1×	1.2k 1.7×	218 0.4×	328 0.6×	365 0.9×	27	2.0k

Countries citing papers authored by Erik Teugels

Since Specialization

Citations

This map shows the geographic impact of Erik Teugels's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Teugels with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Teugels more than expected).

Fields of papers citing papers by Erik Teugels

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Teugels. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Teugels. The network helps show where Erik Teugels may publish in the future.

Co-authorship network of co-authors of Erik Teugels

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Teugels. A scholar is included among the top collaborators of Erik Teugels based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Teugels. Erik Teugels is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joris, Sofie, Philippe Giron, Catharina Olsen, et al.. (2024). Identification of RAD17 as a candidate cancer predisposition gene in families with histories of pancreatic and breast cancers. BMC Cancer. 24(1). 723–723. 1 indexed citations

Willard‐Gallo, Karen, Gert Van den Eynden, Roberto Salgado, et al.. (2019). The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History. Pathology & Oncology Research. 26(2). 1221–1228. 7 indexed citations

Noeparast, Amir, Philippe Giron, Sylvia De Brakeleer, et al.. (2019). CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibition. Oncogene. 38(31). 5933–5941. 22 indexed citations

Teugels, Erik & Sylvia De Brakeleer. (2017). An alternative model for (breast) cancer predisposition. npj Breast Cancer. 3(1). 13–13. 4 indexed citations

Willard‐Gallo, Karen, Gert Van den Eynden, Roberto Salgado, et al.. (2017). P3.02c-087 The Relationship of TILs and PD-L1 Expression in NSCLC Adenocarcinoma in Little to Non-Smokers with Driver Mutations and Outcome Parameters. Journal of Thoracic Oncology. 12(1). S1331–S1331. 1 indexed citations

Grève, Jacques De, Jan P. van Meerbeeck, Johan Vansteenkiste, et al.. (2016). Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT). PLoS ONE. 11(3). e0147599–e0147599. 16 indexed citations

Brakeleer, Sylvia De, et al.. (2014). Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods. Applied immunohistochemistry & molecular morphology. 23(3). 163–171. 13 indexed citations

Teugels, Erik, Jan Sadones, Sylvia De Brakeleer, et al.. (2012). Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. International Journal of Oncology. 41(3). 1029–1035. 56 indexed citations

Grève, Jacques De, Jan P. van Meerbeeck, Johan Vansteenkiste, et al.. (2011). First-line erlotinib in advanced non-small cell lung cancer (NSCLC) carrying an activating EGFR mutation: A multicentre academic phase II study in caucasian patients (pts) (NCT00339586). Journal of Clinical Oncology. 1 indexed citations

10.

Hočevar, Marko, et al.. (2011). BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. Neoplasma. 58(3). 198–204. 5 indexed citations

11.

Brakeleer, Sylvia De, Jacques De Grève, Remy Loris, et al.. (2010). Cancer predisposing missense and protein truncatingBARD1mutations in non-BRCA1orBRCA2breast cancer families. Human Mutation. 31(3). E1175–E1185. 68 indexed citations

12.

Grève, Jacques De, Lore Decoster, Johan De Mey, et al.. (2009). Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu. Journal of Thoracic Oncology. 4. 307–307. 20 indexed citations

13.

Chen, Gang, Peter Kronenberger, Ijeoma Adaku Umelo, Erik Teugels, & Jacques De Grève. (2009). Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase–quantitative polymerase chain reaction. Analytical Biochemistry. 398(2). 266–268. 20 indexed citations

14.

Bešič, Nikola, Jacques De Grève, Mateja Krajc, et al.. (2008). BRCA2 Gene Mutations in Slovenian Male Breast Cancer Patients. Genetic Testing. 12(2). 203–209. 15 indexed citations

15.

Grève, Jacques De, et al.. (2008). Hereditary breast cancer: from bench to bedside. Current Opinion in Oncology. 20(6). 605–613. 19 indexed citations

16.

Brakeleer, Sylvia De, Marika Bogdani, Jacques De Grève, et al.. (2007). Loss of nuclear BRCA1 protein staining in normal tissue cells derived from BRCA1 and BRCA2 mutation carriers. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 619(1-2). 104–112. 6 indexed citations

17.

Krajc, Mateja, et al.. (2002). BRCA2 founder mutation in Slovenian breast cancer families. European Journal of Human Genetics. 10(12). 879–882. 18 indexed citations

18.

Vermeij, Joanna, et al.. (2001). Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. British Journal of Cancer. 85(10). 1592–1599. 14 indexed citations

19.

Vermeulen, Stefan, Friedel Nollet, Erik Teugels, et al.. (1999). The αE-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells. Oncogene. 18(4). 905–915. 64 indexed citations

20.

Hooghe‐Peters, E. L., Erik Teugels, Frank Roels, B. Velkeniers, & L. Vanhaelst. (1991). Quantitative in Situ Hybridization in Neuro-Endocrinology. Pathology - Research and Practice. 187(5). 564–566. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact